Molecular Neurodegeneration (Jan 2010)

Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and <it>PSEN1 </it>A431E-associated familial Alzheimer's disease

  • Galasko Douglas,
  • Hanse Eric,
  • Gustavsson Mikael K,
  • Harmsen Andreas,
  • Hansson Oskar,
  • Buchhave Peder,
  • Daborg Jonny,
  • Buerger Katharina,
  • Ringman John M,
  • Andreasson Ulf,
  • Portelius Erik,
  • Hampel Harald,
  • Blennow Kaj,
  • Zetterberg Henrik

DOI
https://doi.org/10.1186/1750-1326-5-2
Journal volume & issue
Vol. 5, no. 1
p. 2

Abstract

Read online

Abstract Background Alzheimer's disease (AD) is associated with deposition of amyloid β (Aβ) in the brain, which is reflected by low concentration of the Aβ1-42 peptide in the cerebrospinal fluid (CSF). There are at least 15 additional Aβ peptides in human CSF and their relative abundance pattern is thought to reflect the production and degradation of Aβ. Here, we test the hypothesis that AD is characterized by a specific CSF Aβ isoform pattern that is distinct when comparing sporadic AD (SAD) and familial AD (FAD) due to different mechanisms underlying brain amyloid pathology in the two disease groups. Results We measured Aβ isoform concentrations in CSF from 18 patients with SAD, 7 carriers of the FAD-associated presenilin 1 (PSEN1) A431E mutation, 17 healthy controls and 6 patients with depression using immunoprecipitation-mass spectrometry. Low CSF levels of Aβ1-42 and high levels of Aβ1-16 distinguished SAD patients and FAD mutation carriers from healthy controls and depressed patients. SAD and FAD were characterized by similar changes in Aβ1-42 and Aβ1-16, but FAD mutation carriers exhibited very low levels of Aβ1-37, Aβ1-38 and Aβ1-39. Conclusion SAD patients and PSEN1 A431E mutation carriers are characterized by aberrant CSF Aβ isoform patterns that hold clinically relevant diagnostic information. PSEN1 A431E mutation carriers exhibit low levels of Aβ1-37, Aβ1-38 and Aβ1-39; fragments that are normally produced by γ-secretase, suggesting that the PSEN1 A431E mutation modulates γ-secretase cleavage site preference in a disease-promoting manner.